[{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"Il-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Emapalumab","moa":"INF gamma","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"Il-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"National Health Service (NHS)","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Efmoroctocog alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ National Health Service (NHS)","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ National Health Service (NHS)"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rFVIIIFc-VWF-XTEN","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Emapalumab","moa":"INF gamma","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Swedish Orphan Biovitrum AB","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rFVIIIFc-VWF-XTEN","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nitisinone","moa":"HPDD","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegadricase","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegadricase","moa":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":1.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":1.25,"dosageForm":"Intravitreal Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Neurology","graph2":"Phase II","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Apellis"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"TYK","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Efanesoctocog alfa","moa":"VWF","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Hellenic Institute for the Study of Sepsis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Hellenic Institute for the Study of Sepsis","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Hellenic Institute for the Study of Sepsis"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Eftrenonacog Alfa","moa":"Coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Agnafit Bidco","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Efmoroctocog Alfa","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":8,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":8,"dosageForm":"Powder and Solvent for Solution for Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Agnafit Bidco","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Agnafit Bidco"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"kinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi ","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi "},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Emapalumab","moa":"INF gamma","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Onco360","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ CTI BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ CTI BioPharma"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/IRAK1","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"VWF","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Emapalumab-lzsg","moa":"INF gamma","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sobi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Emapalumab-lzsg","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Termination","leadProduct":"Nirsevimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Nirsevimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"CTI BioPharma Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":1.7,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"CTI BioPharma Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":1.7,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0.70999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.70999999999999996,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Emapalumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Not Applicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"14","companyTruncated":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Pegcetacoplan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"14","companyTruncated":"Swedish Orphan Biovitrum AB \/ Swedish Orphan Biovitrum AB"}]
Find Clinical Drug Pipeline Developments & Deals by Swedish Orphan Biovitrum AB
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
